You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Avatamed will use the funds to expand into the Asia-Pacific market and set up a lab in Singapore to provide precision cancer drug screening services.
The company, which uses fruit fly "avatars" to screen drugs, will be collaborating with London IVD Co-operative and Genomics England to test their technology in GI cancer patients.
The researchers said their new study supports the clinical utility of their test, which combines genomic and drug screening analyses of organoids to guide cancer treatment.
Of the eight patients who received drugs recommended by the tumor board based on data from the drug sensitivity assay, 75 percent responded.
Initial data on the PARIS test, combining functional drug testing and DNA sequencing, showed concordance between its predictions and patients' treatment responses.
The ROS1ders advocacy group is 500 patients strong and they are helping researchers establish cell lines to improve understanding of rare ROS1-positve cancers.
The Seattle-based firm will use the funding to improve AI integration and further develop its Paris 3D tumor organoid diagnostic and drug discovery platform.
The Canadian company said its technology platform allows it to match patients to cancer treatments more efficiently and to identify novel patient populations.
The researchers created a resource of cancer dependencies and developed a framework to prioritize existing cancer drug targets and suggest new ones.